ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Acute Respiratory Distress Syndrome Therapeutics Market Insights, Forecast to 2029
Published Date: August 2023
|
Report Code: QYRE-Auto-5W13922
Home | Market Reports | Health| Health Conditions
Global Acute Respiratory Distress Syndrome Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Acute Respiratory Distress Syndrome Therapeutics Market Insights, Forecast to 2029

Code: QYRE-Auto-5W13922
Report
August 2023
Pages:113
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Therabron Therapeutics Inc
Serendex Pharmaceuticals A/S
Silence Therapeutics Plc
Histocell S.L.
Altor BioScience Corporation
Athersys
Faron Pharmaceuticals Oy
FirstString Research Inc
GlaxoSmithKline PLC
Phylogica Ltd

Acute Respiratory Distress Syndrome Therapeutics Market Size

The global Acute Respiratory Distress Syndrome Therapeutics market is projected to grow from US$ 391.2 million in 2023 to US$ 469.8 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.1% during the forecast period.

Acute Respiratory Distress Syndrome Therapeutics Market

Acute Respiratory Distress Syndrome Therapeutics Market

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
Market Analysis and Insights: Global Acute Respiratory Distress Syndrome Therapeutics Market
North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.
Report Includes
This report presents an overview of global market for Acute Respiratory Distress Syndrome Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Acute Respiratory Distress Syndrome Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Acute Respiratory Distress Syndrome Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Acute Respiratory Distress Syndrome Therapeutics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Acute Respiratory Distress Syndrome Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Acute Respiratory Distress Syndrome Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Therabron Therapeutics, Inc., Serendex Pharmaceuticals A/S, Silence Therapeutics Plc, Histocell S.L., Altor BioScience Corporation, Athersys, Inc., Faron Pharmaceuticals Oy, FirstString Research, Inc. and GlaxoSmithKline Plc, etc.

Scope of Acute Respiratory Distress Syndrome Therapeutics Market Report

Report Metric Details
Report Name Acute Respiratory Distress Syndrome Therapeutics Market
Accounted market size in 2023 US$ 391.2 million
Forecasted market size in 2029 US$ 469.8 million
CAGR 3.1
Base Year 2023
Forecasted years 2023 - 2029
Segment by Type
  • Methylprednisolone
  • Hydrocortisone
  • Calf Pulmonary Surfactant for Injection
  • Others
Segment by Application
  • In-Patient
  • Out-Patient
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Therabron Therapeutics, Inc., Serendex Pharmaceuticals A/S, Silence Therapeutics Plc, Histocell S.L., Altor BioScience Corporation, Athersys, Inc., Faron Pharmaceuticals Oy, FirstString Research, Inc., GlaxoSmithKline Plc, Phylogica Limited
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Acute Respiratory Distress Syndrome Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Acute Respiratory Distress Syndrome Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America by type, by application and by country, revenue for each segment.
  • Chapter 7: Europe by type, by application and by country, revenue for each segment.
  • Chapter 8: China by type and by application revenue for each segment.
  • Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Respiratory Distress Syndrome Therapeutics revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Acute Respiratory Distress Syndrome Therapeutics Market growing?

Ans: The Acute Respiratory Distress Syndrome Therapeutics Market witnessing a CAGR of 3.1 during the forecast period 2023-2029.

What is the Acute Respiratory Distress Syndrome Therapeutics Market size in 2029?

Ans: The global Acute Respiratory Distress Syndrome Therapeutics market is projected to grow from US$ 391.2 million in 2023 to US$ 469.8 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.1% during the forecast period.

What is the Acute Respiratory Distress Syndrome Therapeutics Market share by region?

Ans: North America is the largest consumption place, with a consumption market share nearly 33% .

What is the market share of major companies in Acute Respiratory Distress Syndrome Therapeutics Market?

Ans: Top 3 companies occupied about 85% market share.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Methylprednisolone
1.2.3 Hydrocortisone
1.2.4 Calf Pulmonary Surfactant for Injection
1.2.5 Others
1.3 Market by Application
1.3.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 In-Patient
1.3.3 Out-Patient
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Perspective (2018-2029)
2.2 Global Acute Respiratory Distress Syndrome Therapeutics Growth Trends by Region
2.2.1 Acute Respiratory Distress Syndrome Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Respiratory Distress Syndrome Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Acute Respiratory Distress Syndrome Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Acute Respiratory Distress Syndrome Therapeutics Market Dynamics
2.3.1 Acute Respiratory Distress Syndrome Therapeutics Industry Trends
2.3.2 Acute Respiratory Distress Syndrome Therapeutics Market Drivers
2.3.3 Acute Respiratory Distress Syndrome Therapeutics Market Challenges
2.3.4 Acute Respiratory Distress Syndrome Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Acute Respiratory Distress Syndrome Therapeutics by Players
3.1.1 Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Acute Respiratory Distress Syndrome Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Acute Respiratory Distress Syndrome Therapeutics Market Concentration Ratio
3.4.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Respiratory Distress Syndrome Therapeutics Revenue in 2022
3.5 Global Key Players of Acute Respiratory Distress Syndrome Therapeutics Head office and Area Served
3.6 Global Key Players of Acute Respiratory Distress Syndrome Therapeutics, Product and Application
3.7 Global Key Players of Acute Respiratory Distress Syndrome Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Respiratory Distress Syndrome Therapeutics Breakdown Data by Type
4.1 Global Acute Respiratory Distress Syndrome Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Acute Respiratory Distress Syndrome Therapeutics Forecasted Market Size by Type (2024-2029)
5 Acute Respiratory Distress Syndrome Therapeutics Breakdown Data by Application
5.1 Global Acute Respiratory Distress Syndrome Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Acute Respiratory Distress Syndrome Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Acute Respiratory Distress Syndrome Therapeutics Market Size (2018-2029)
6.2 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type
6.2.1 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023)
6.2.2 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029)
6.2.3 North America Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
6.3 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application
6.3.1 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023)
6.3.2 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029)
6.3.3 North America Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
6.4 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
6.4.1 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2018-2023)
6.4.3 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size (2018-2029)
7.2 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Type
7.2.1 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023)
7.2.2 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029)
7.2.3 Europe Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
7.3 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Application
7.3.1 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023)
7.3.2 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029)
7.3.3 Europe Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
7.4 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
7.4.1 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2018-2023)
7.4.3 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Acute Respiratory Distress Syndrome Therapeutics Market Size (2018-2029)
8.2 China Acute Respiratory Distress Syndrome Therapeutics Market Size by Type
8.2.1 China Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023)
8.2.2 China Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029)
8.2.3 China Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
8.3 China Acute Respiratory Distress Syndrome Therapeutics Market Size by Application
8.3.1 China Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023)
8.3.2 China Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029)
8.3.3 China Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size (2018-2029)
9.2 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Type
9.2.1 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023)
9.2.2 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029)
9.2.3 Asia Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
9.3 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Application
9.3.1 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023)
9.3.2 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029)
9.3.3 Asia Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
9.4 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Region
9.4.1 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Region (2018-2023)
9.4.3 Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Therabron Therapeutics, Inc.
11.1.1 Therabron Therapeutics, Inc. Company Details
11.1.2 Therabron Therapeutics, Inc. Business Overview
11.1.3 Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Introduction
11.1.4 Therabron Therapeutics, Inc. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.1.5 Therabron Therapeutics, Inc. Recent Developments
11.2 Serendex Pharmaceuticals A/S
11.2.1 Serendex Pharmaceuticals A/S Company Details
11.2.2 Serendex Pharmaceuticals A/S Business Overview
11.2.3 Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Introduction
11.2.4 Serendex Pharmaceuticals A/S Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.2.5 Serendex Pharmaceuticals A/S Recent Developments
11.3 Silence Therapeutics Plc
11.3.1 Silence Therapeutics Plc Company Details
11.3.2 Silence Therapeutics Plc Business Overview
11.3.3 Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Introduction
11.3.4 Silence Therapeutics Plc Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.3.5 Silence Therapeutics Plc Recent Developments
11.4 Histocell S.L.
11.4.1 Histocell S.L. Company Details
11.4.2 Histocell S.L. Business Overview
11.4.3 Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Introduction
11.4.4 Histocell S.L. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.4.5 Histocell S.L. Recent Developments
11.5 Altor BioScience Corporation
11.5.1 Altor BioScience Corporation Company Details
11.5.2 Altor BioScience Corporation Business Overview
11.5.3 Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Introduction
11.5.4 Altor BioScience Corporation Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.5.5 Altor BioScience Corporation Recent Developments
11.6 Athersys, Inc.
11.6.1 Athersys, Inc. Company Details
11.6.2 Athersys, Inc. Business Overview
11.6.3 Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Introduction
11.6.4 Athersys, Inc. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.6.5 Athersys, Inc. Recent Developments
11.7 Faron Pharmaceuticals Oy
11.7.1 Faron Pharmaceuticals Oy Company Details
11.7.2 Faron Pharmaceuticals Oy Business Overview
11.7.3 Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Introduction
11.7.4 Faron Pharmaceuticals Oy Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.7.5 Faron Pharmaceuticals Oy Recent Developments
11.8 FirstString Research, Inc.
11.8.1 FirstString Research, Inc. Company Details
11.8.2 FirstString Research, Inc. Business Overview
11.8.3 FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Introduction
11.8.4 FirstString Research, Inc. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.8.5 FirstString Research, Inc. Recent Developments
11.9 GlaxoSmithKline Plc
11.9.1 GlaxoSmithKline Plc Company Details
11.9.2 GlaxoSmithKline Plc Business Overview
11.9.3 GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Introduction
11.9.4 GlaxoSmithKline Plc Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.9.5 GlaxoSmithKline Plc Recent Developments
11.10 Phylogica Limited
11.10.1 Phylogica Limited Company Details
11.10.2 Phylogica Limited Business Overview
11.10.3 Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Introduction
11.10.4 Phylogica Limited Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
11.10.5 Phylogica Limited Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Therabron Therapeutics Inc
Serendex Pharmaceuticals A/S
Silence Therapeutics Plc
Histocell S.L.
Altor BioScience Corporation
Athersys
Faron Pharmaceuticals Oy
FirstString Research Inc
GlaxoSmithKline PLC
Phylogica Ltd
List of Tables
    Table 1. Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
    Table 2. Key Players of Methylprednisolone
    Table 3. Key Players of Hydrocortisone
    Table 4. Key Players of Calf Pulmonary Surfactant for Injection
    Table 5. Key Players of Others
    Table 6. Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
    Table 7. Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 9. Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Region (2018-2023)
    Table 10. Global Acute Respiratory Distress Syndrome Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 11. Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Region (2024-2029)
    Table 12. Acute Respiratory Distress Syndrome Therapeutics Market Trends
    Table 13. Acute Respiratory Distress Syndrome Therapeutics Market Drivers
    Table 14. Acute Respiratory Distress Syndrome Therapeutics Market Challenges
    Table 15. Acute Respiratory Distress Syndrome Therapeutics Market Restraints
    Table 16. Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Players (2018-2023) & (US$ Million)
    Table 17. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Players (2018-2023)
    Table 18. Global Top Acute Respiratory Distress Syndrome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Respiratory Distress Syndrome Therapeutics as of 2022)
    Table 19. Global Acute Respiratory Distress Syndrome Therapeutics Industry Ranking 2021 VS 2022 VS 2023
    Table 20. Global 5 Largest Players Market Share by Acute Respiratory Distress Syndrome Therapeutics Revenue (CR5 and HHI) & (2018-2023)
    Table 21. Global Key Players of Acute Respiratory Distress Syndrome Therapeutics, Headquarters and Area Served
    Table 22. Global Key Players of Acute Respiratory Distress Syndrome Therapeutics, Product and Application
    Table 23. Global Key Players of Acute Respiratory Distress Syndrome Therapeutics, Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 26. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Type (2018-2023)
    Table 27. Global Acute Respiratory Distress Syndrome Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 28. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Type (2024-2029)
    Table 29. Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 30. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Application (2018-2023)
    Table 31. Global Acute Respiratory Distress Syndrome Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 32. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Application (2024-2029)
    Table 33. North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 34. North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 35. North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 36. North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 37. North America Acute Respiratory Distress Syndrome Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 38. North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 39. North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 40. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 41. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 42. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 43. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 44. Europe Acute Respiratory Distress Syndrome Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 45. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 46. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 47. China Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 48. China Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 49. China Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 50. China Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 51. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 52. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 53. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 54. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 55. Asia Acute Respiratory Distress Syndrome Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 56. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 57. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size by Region (2024-2029) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 63. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 65. Therabron Therapeutics, Inc. Company Details
    Table 66. Therabron Therapeutics, Inc. Business Overview
    Table 67. Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Product
    Table 68. Therabron Therapeutics, Inc. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 69. Therabron Therapeutics, Inc. Recent Developments
    Table 70. Serendex Pharmaceuticals A/S Company Details
    Table 71. Serendex Pharmaceuticals A/S Business Overview
    Table 72. Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Product
    Table 73. Serendex Pharmaceuticals A/S Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 74. Serendex Pharmaceuticals A/S Recent Developments
    Table 75. Silence Therapeutics Plc Company Details
    Table 76. Silence Therapeutics Plc Business Overview
    Table 77. Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Product
    Table 78. Silence Therapeutics Plc Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 79. Silence Therapeutics Plc Recent Developments
    Table 80. Histocell S.L. Company Details
    Table 81. Histocell S.L. Business Overview
    Table 82. Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Product
    Table 83. Histocell S.L. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 84. Histocell S.L. Recent Developments
    Table 85. Altor BioScience Corporation Company Details
    Table 86. Altor BioScience Corporation Business Overview
    Table 87. Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Product
    Table 88. Altor BioScience Corporation Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 89. Altor BioScience Corporation Recent Developments
    Table 90. Athersys, Inc. Company Details
    Table 91. Athersys, Inc. Business Overview
    Table 92. Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Product
    Table 93. Athersys, Inc. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 94. Athersys, Inc. Recent Developments
    Table 95. Faron Pharmaceuticals Oy Company Details
    Table 96. Faron Pharmaceuticals Oy Business Overview
    Table 97. Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Product
    Table 98. Faron Pharmaceuticals Oy Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 99. Faron Pharmaceuticals Oy Recent Developments
    Table 100. FirstString Research, Inc. Company Details
    Table 101. FirstString Research, Inc. Business Overview
    Table 102. FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Product
    Table 103. FirstString Research, Inc. Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 104. FirstString Research, Inc. Recent Developments
    Table 105. GlaxoSmithKline Plc Company Details
    Table 106. GlaxoSmithKline Plc Business Overview
    Table 107. GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Product
    Table 108. GlaxoSmithKline Plc Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 109. GlaxoSmithKline Plc Recent Developments
    Table 110. Phylogica Limited Company Details
    Table 111. Phylogica Limited Business Overview
    Table 112. Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Product
    Table 113. Phylogica Limited Revenue in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023) & (US$ Million)
    Table 114. Phylogica Limited Recent Developments
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 2. Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Type: 2022 VS 2029
    Figure 3. Methylprednisolone Features
    Figure 4. Hydrocortisone Features
    Figure 5. Calf Pulmonary Surfactant for Injection Features
    Figure 6. Others Features
    Figure 7. Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 8. Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Application: 2022 VS 2029
    Figure 9. In-Patient Case Studies
    Figure 10. Out-Patient Case Studies
    Figure 11. Acute Respiratory Distress Syndrome Therapeutics Report Years Considered
    Figure 12. Global Acute Respiratory Distress Syndrome Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 13. Global Acute Respiratory Distress Syndrome Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 14. Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Region: 2022 VS 2029
    Figure 15. Global Acute Respiratory Distress Syndrome Therapeutics Market Share by Players in 2022
    Figure 16. Global Top Acute Respiratory Distress Syndrome Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Respiratory Distress Syndrome Therapeutics as of 2022)
    Figure 17. The Top 10 and 5 Players Market Share by Acute Respiratory Distress Syndrome Therapeutics Revenue in 2022
    Figure 18. North America Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 19. North America Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
    Figure 20. North America Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
    Figure 21. North America Acute Respiratory Distress Syndrome Therapeutics Market Share by Country (2018-2029)
    Figure 22. United States Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Canada Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Europe Acute Respiratory Distress Syndrome Therapeutics Market Size YoY (2018-2029) & (US$ Million)
    Figure 25. Europe Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
    Figure 26. Europe Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
    Figure 27. Europe Acute Respiratory Distress Syndrome Therapeutics Market Share by Country (2018-2029)
    Figure 28. Germany Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. France Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. U.K. Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Italy Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Russia Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Nordic Countries Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. China Acute Respiratory Distress Syndrome Therapeutics Market Size YoY (2018-2029) & (US$ Million)
    Figure 35. China Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
    Figure 36. China Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
    Figure 37. Asia Acute Respiratory Distress Syndrome Therapeutics Market Size YoY (2018-2029) & (US$ Million)
    Figure 38. Asia Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
    Figure 39. Asia Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
    Figure 40. Asia Acute Respiratory Distress Syndrome Therapeutics Market Share by Region (2018-2029)
    Figure 41. Japan Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. South Korea Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. China Taiwan Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Southeast Asia Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. India Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Australia Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Size YoY (2018-2029) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Share by Type (2018-2029)
    Figure 49. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Share by Application (2018-2029)
    Figure 50. Middle East, Africa, and Latin America Acute Respiratory Distress Syndrome Therapeutics Market Share by Country (2018-2029)
    Figure 51. Brazil Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 52. Mexico Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 53. Turkey Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 54. Saudi Arabia Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 55. Israel Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 56. GCC Countries Acute Respiratory Distress Syndrome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 57. Therabron Therapeutics, Inc. Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 58. Serendex Pharmaceuticals A/S Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 59. Silence Therapeutics Plc Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 60. Histocell S.L. Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 61. Altor BioScience Corporation Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 62. Athersys, Inc. Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 63. Faron Pharmaceuticals Oy Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 64. FirstString Research, Inc. Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 65. GlaxoSmithKline Plc Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 66. Phylogica Limited Revenue Growth Rate in Acute Respiratory Distress Syndrome Therapeutics Business (2018-2023)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Pulmonary Exerciser - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-20C16992
Thu May 02 00:00:00 UTC 2024

Add to Cart

Medical Nasal Stent - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-2P14533
Thu May 02 00:00:00 UTC 2024

Add to Cart

Pediatric Ventricular Assist Device - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-37H14530
Thu May 02 00:00:00 UTC 2024

Add to Cart

Synthetic Fiber Vascular Prosthesis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-38F13932
Thu May 02 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions